Interview with Howard Balloch, President, The Balloch Group
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
Address: Canaccord Genuity Asia
Suite C700, 50 Liangmaqiao Rd.
Beijing 100125
China
Tel: 8610-8451-5559
Web: http://www.加通贝祥.com/en/Pages/default.aspx
The Balloch Group (‘TBG’) was established in 2001 by Howard Balloch (Canada’s ambassador to China from 1996 to 2001). TBG has since grown from a market-entry consultancy working with North American clients in China to a leading advisory and merchant banking firm serving both domestic Chinese companies and multinational corporations. TBG was ranked as the number one boutique investment bank in China by ChinaVenture in 2008.
TBG’s professionals are located in Beijing, New York, Shanghai, Hong Kong, Wuhan and Hangzhou serving and investing alongside clients in mergers and acquisitions, capital markets and direct investment transactions.
Advisory Services, Direct Investment
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
Writing in the September 2023 edition of DIA’s Global Forum magazine, Shuting Li of Anhui Jimin Cancer Hospital and Xinfang Fan of Bayer Health Care Ltd. examine how Chinese clinical…
Ongoing geopolitical tensions between China and the West have led the G7 group of countries to warn of the threat of “economic coercion” from China and the US to scrutinise…
A roundup of some of the latest healthcare and pharma news from China including a crackdown on healthcare corruption; AstraZeneca’s cardiovascular mortality drug approval and mRNA manufacturing deal with CanSino;…
Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years…
At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively…
A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s…
A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political…
Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of…
The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from…
China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further…
The latest news from the Chinese healthcare and life sciences industry, including the first public comments from Astellas CEO Naoki Okamura following an employee’s arrest on espionage charges in China,…
John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With…
See our Cookie Privacy Policy Here